The development of noninvasive imaging techniques using monoclonal antibodies (mAbs)
is a quickly evolving field. Immuno-PET uses positron-emitting isotopes to track the …

Summation Monoclonal antibodies (mAbs) have been approved for therapeutic use in a
broad range of medical indications, especially in oncology, and are forming the most rapidly …

The identification of molecular drivers of disease and the compelling rise of biotherapeutics
have impacted clinical care but have also come with challenges. Such therapeutics include …

Summation The identification of tumor tissue biomarkers has led to the production,
validation, and Food and Drug Administration-approval of a number of antibody-based …

Purpose Immuno-PET is an emerging imaging tool for the selection of high potential
antibodies (mAbs) for imaging and therapy. The positron emitter zirconium-89 (89 Zr) has …

Positron emission tomography (PET) with 89Zr-labeled monoclonal antibodies (mAbs) or
other targeted vehicles (eg., peptides, nanoparticles and cells), collectively called “89Zr …

89Zr-immuno-PET is a promising noninvasive clinical tool that measures target engagement
of monoclonal antibodies (mAbs) to predict toxicity in normal tissues and efficacy in tumors …

Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT)
candidates to confirm tumor targeting and to estimate radiation doses to tumor and normal …

The use of immuno-PET, the combination of PET with monoclonal antibodies (mAbs), is an
attractive option to improve tumor detection and mAb quantification. The long-lived positron …

Monoclonal antibodies are approved for use as diagnostics and therapeutics in a broad
range of medical indications including transplantation, cardiology, inflammatory diseases …